DURHAM, N.C., United States and BEIJING, China – March 17, 2022 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that it will present data from its Phase 2 study evaluating the safety and antiviral activity of two monthly doses of BRII-835 (VIR-2218) in patients with chronic hepatitis B virus (HBV) infection as an oral presentation at the 31st Conference of Asian Pacific Association for the Study of the Liver (APASL 2022), being held from March 30 – April 3, 2022 in Seoul, Korea.

Additional details of the presentation are as follows:

Abstract Number: L-OP-1324
Presentation Title: Safety and antiviral activity of two monthly administrations of BRII-835 (VIR-2218), an X-targeting RNAi therapeutic, in Chinese patients with chronic HBV infection
Presenter: Jidong Jia, MD, PhD, Professor of Medicine at Capital Medical University and Director of the Liver Research Centre at Beijing Friendship Hospital in Beijing, China.

About BRII-835 (VIR-2218)

BRII-835 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. Brii Bio licensed exclusive rights to develop and commercialize VIR-2218 for the greater China territory from Vir Biotechnology, Inc. (“Vir”) in 2020.

Meanwhile, BRII-835 (VIR-2218) is being investigated in three additional Phase 2 studies, sponsored by Brii and Vir, respectively, in combinations with BRII-179 (a recombinant therapeutic vaccine), PEG-IFN-alpha and/or VIR-3434 (a monoclonal antibody targeting HBV) as a functional cure regimen for chronic HBV infection.

About Hepatitis B

Hepatitis B is one of the world’s most significant infectious disease threats, with more than 290 million people infected globally. HBV infection is the leading cause of liver disease, and, with current treatments, it is very difficult to cure, and many patients go on to develop liver cancers. An estimated 780,000 people die each year from complications of chronic HBV, such as liver decompensation and hepatocellular carcinoma.

About Brii Bio

Brii Biosciences Limited (“Brii Bio”, or the “Company”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide. For more information, visit www.briibio.com.

Media Inquiry:

media@briibio.com
Summer Li (China)
+86-135-2191-1607
Ben Shannon (U.S.)
+1-919-360-3039

Investor Inquiry:

ir@briibio.com
Chris Fang
+86-139-1692-8049